Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. Issue 2 (14th May 2021)

• Record Type: Journal Article
• Authors: Mansouri, Alireza; Beyn, Michelle E; Pancholi, Aditya; Chow, Clement T; Wang, Ryan; Boutet, Alexandre; Elias, Gavin J B; Germann, Jurgen; Loh, Aaron; Voisin, Mathew R; Lozano, Andres M; Chiocca, E Antonio; Vogelbaum, Michael A; Zadeh, Gelareh
• Is Part Of: Neurosurgery. Volume 89:Issue 2(2021)
• Page Start: 196
• Page End: 203
• Publication Date: 2021-05-14
• Subjects: Clinical trials -- Glioblastoma -- Neuro-oncology; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyab169
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: BACKGROUND: The therapeutic challenge of glioblastoma (GBM) has catalyzed the development of clinical trials to evaluate novel interventions. With increased understanding of GBM biology and technological advances, the neurosurgeon's role in neuro-oncology has evolved. OBJECTIVE: To evaluate the current landscape of procedure-based clinical trials for GBM to characterize this evolution, gain insight into past failures, and accordingly outline implications for future research and practice that may inform future studies. METHODS: The ClinicalTrials.gov database was searched for surgical/procedural trials in individuals with GBM. Demographics, specific intervention, trial phase, and main outcome measures were abstracted. RESULTS: A total of 224 of 2311 GBM trials (9.7%) were identified as procedural, with the majority being based in the United States (155/224, 69.2%), single-center (155/224, 69.2%), and not randomized (176/224, 78.6%). Primary and recurrent GBMs were evenly addressed. The leading interventions were local delivery of therapeutics (50.0%), surgical techniques (33.9%), such as image-guided surgery, and novel device applications (14.3%). Phase I designs predominated (82/224, 36.6%). The top primary outcome was safety/tolerability/feasibility (88/224, 39.3%), followed by survival (46/224, 20.5%). Approximately 17% of studies were terminated, withdrawn, or suspended. Fifty-two linked publications were identified, among which 42 were classified as having a positive result. CONCLUSION: Procedural interventions comprised ∼10% of all registered GBM trials. Local delivery of therapeutics, use of surgical imaging techniques and novel device applications, predominantly through phase I designs, represent the evolved role of the neurosurgeon in neuro-oncology. Improved reporting of trial designs, outcomes, and results are needed to better inform the field and increase efficiency.